IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(s): Jose Esteve-Soler, et al.

SERIAL NO.: 10/536,782 ART UNIT:

FILING DATE: 11/23/05 EXAMINER:

TITLE: USE OF 2, 5-DIHYDROXYBENZENESULFONIC COMPOUNDS

FOR THE TREATMENT OF DISORDERS BASED ON AN IMPAIRMENT OF NO PRODUCTION AND/OR OF

REGULATION OF EDHF FUNCTION

ATTORNEY

DOCKET NO.: 785-012246-US (PAR)

Commissioner of Patents

P.O. Box 1450

Alexandría, VA 22313-1450

information disclosure statement (37 c.f.r. §1.97(b)(3))

Sir:

This information disclosure statement is being filed before the mailing of a first Office Action on the merits.

The following information is being disclosed to the Patent and Trademark Office as information that may be material to the examination of the above-identified patent application. Applicants' Attorney is aware of the following reference:

"Metabolisme et pharmacocinetique du dobesilate de calcium chez l'Homme (1)", A. Benakis, et al., Therapie, 1974, 29, 211-219

A copy of this reference is enclosed together with a Form PTO-1449. The filing of this Statement is not to be construed as a representation that a search has been made regarding the claimed invention (37 C.F.R. §1.97(g)) or that no other possible material information exists. In addition, the filing of this Information Disclosure Statement is not to be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability (37 C.F.R. \$1.97(h)).

Respectfully submitted,

Geza C. Ziegler, Reg. No. 44,004

PERMAN & GREEN, LLP 425 Post Road

Fairfield, CT 068424

Customer No. 2512

Approved for use through 09/30/2006, OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPART MENT OF COMMERCE

| Under the Paperwork Reduction Act of 1995, no persons an Substitute for form 1449/PTO | re required to respond to a cultection of information unless it contains a valid OMB control number Complete if Known | | |
|--|--|---------------------------|--|
| Substitute an anti-company of | Application Number | 10/536,782 | |
| INFORMATION DISCLOSURE | Filing Date | 11/23/05 | |
| STATEMENT BY APPLICANT | First Named Inventor | Jose Esteve-Soler, et al. | |
| | Art Unit | | |
| (Use as many sheets as necessory) | Examiner Name | | |
| Sheet 1 of 1 | Attorney Docket Number | 785-012246-US (PAR) | |

| | | NON PATENT LITERATURE DOCUMENTS | |
|-----------------------|-------------|---|---------|
| Examiner Initials* | Cite No. | include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T2 |
| | | "Metabolisme et pharmacocinetique du dobesilate de calcium chez l'Homme(1)", A. Benakis, et al., Therapie, 1974, 29, 211-219 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| Examiner | Date | |
|-----------|------------|--|
| Signature | Considered | |

^{*}EXAMINER* Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with first committed to appears.

1 Applicant is unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.38. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. **Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Awarandria, VA 22313-1458. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.